Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Boehringer Ingelheim GmbH - Product Pipeline Review - 2013

Published: Dec-2013 | Format: PDF | Global Markets Direct | Number of pages: 171 | Code: MRS - 995

Global Market Directs pharmaceuticals report, Boehringer Ingelheim GmbH Product Pipeline Review 2013 provides data on the Boehringer Ingelheim GmbHs research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, Boehringer Ingelheim GmbHs corporate website, SEC filings, investor presentations and featured press releases, both from Boehringer Ingelheim GmbH and industry-specific third party sources, put together by Global Markets Directs team. 

Scope

Boehringer Ingelheim GmbH Brief Boehringer Ingelheim GmbH overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of Boehringer Ingelheim GmbH human therapeutic division.
Overview of pipeline therapeutics across various therapy areas.
Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
Product profiles for late stage and clinical stage products of Boehringer Ingelheim GmbH with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
Recent updates of the Boehringer Ingelheim GmbHs pipeline in the last quarter. 
Key discontinued and dormant projects. 
Latest news and deals relating to the products.

Reasons to buy


Evaluate Boehringer Ingelheim GmbHs strategic position with total access to detailed information on its product pipeline. 
Assess the growth potential of Boehringer Ingelheim GmbH in its therapy areas of focus.
Identify new drug targets and therapeutic classes in the Boehringer Ingelheim GmbHs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
Exploit collaboration and partnership opportunities with Boehringer Ingelheim GmbH. 
Avoid Intellectual Property Rights related issues. 
Explore the dormant and discontinued projects of Boehringer Ingelheim GmbH and identify potential opportunities in those areas.

Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Boehringer Ingelheim GmbH Snapshot 6
Boehringer Ingelheim GmbH Overview 6
Key Information 6
Key Facts 6
Boehringer Ingelheim GmbH - Research and Development Overview 7
Key Therapeutic Areas 7
Boehringer Ingelheim GmbH - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Pipeline Products - Out-Licensed Products 19
Boehringer Ingelheim GmbH - Pipeline Products Glance 21
Boehringer Ingelheim GmbH - Late Stage Pipeline Products 21
Boehringer Ingelheim GmbH - Clinical Stage Pipeline Products 23
Boehringer Ingelheim GmbH - Early Stage Pipeline Products 26
Boehringer Ingelheim GmbH - Drug Profiles 28
afatinib 28
dabigatran etexilate mesylate 31
empagliflozin 33
faldaprevir 35
nintedanib 37
olodaterol 39
tiotropium bromide 41
(empagliflozin + linagliptin) 43
(linagliptin + pioglitazone hydrochloride) 44
(olodaterol + tiotropium bromide) 46
deleobuvir 48
pramipexole dihydrochloride ER 50
rituximab biosimilar 51
volasertib 52
BI-671800 54
BI-811283 55
11Beta HSD-1 Program 56
adalimumab biosimilar 57
ambroxol 58
BI-1005273 59
BI-1015550 60
BI-1021958 61
BI-1026706 62
BI-1034020 63
BI-1060469 65
BI-113608 66
BI-144807 67
BI-163538XX 68
BI-187004-CL 69
BI-2536 70
BI-409306 72
BI-411034 73
BI-655064 74
BI-655066 75
BI-655075 76
BI-661051 77
BI-691751 78
BI-695502 79
BI-836826 80
BI-836845 81
BI-836858 83
BI-847325 84
BI-853520 86
BI-860585 87
ZP-2929 88
BCA-909 89
BIBN-4096BS 91
BILB-1941 92
Drug For Rhinovirus Infection 93
Drug Targeting HIV-1 Reverse Transcriptase 94
FX-125-L 95
Nanobody Program 97
OX-MPI 98
4-Biaryl Proline Inhibitors 99
Antibody Program For Cancer 100
Compound-30 101
Drug For HCV 102
Drug For HIV 103
Drug For HIV-1 104
Drug For HIV-1 Infection 105
Macrocyclic Acyl Sulfonamide 106
NS3 Inhibitor 107
Undisclosed Drug 108
Boehringer Ingelheim GmbH - Pipeline Analysis 109
Boehringer Ingelheim GmbH - Pipeline Products by Therapeutic Class 109
Boehringer Ingelheim GmbH - Pipeline Products by Target 112
Boehringer Ingelheim GmbH - Pipeline Products by Route of Administration 116
Boehringer Ingelheim GmbH - Pipeline Products by Molecule Type 117
Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action 118
Boehringer Ingelheim GmbH - Recent Pipeline Updates 124
Boehringer Ingelheim GmbH - Dormant Projects 157
Boehringer Ingelheim GmbH - Discontinued Pipeline Products 160
Discontinued Pipeline Product Profiles 160
Boehringer Ingelheim GmbH - Company Statement 162
Boehringer Ingelheim GmbH - Locations And Subsidiaries 163
Head Office 163
Other Locations & Subsidiaries 163

Appendix 166
Methodology 166
Coverage 166
Secondary Research 166
Primary Research 166
Expert Panel Validation 166
Contact Us 167
Disclaimer 167

List of Tables

Boehringer Ingelheim GmbH, Key Information 10
Boehringer Ingelheim GmbH, Key Facts 10
Boehringer Ingelheim GmbH - Pipeline by Indication, 2013 12
Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2013 17
Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2013 18
Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2013 19
Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2013 20
Boehringer Ingelheim GmbH - Partnered Products/ Combination Treatment Modalities, 2013 21
Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2013 23
Boehringer Ingelheim GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2013 24
Boehringer Ingelheim GmbH - Pre-Registration, 2013 25
Boehringer Ingelheim GmbH - Phase III, 2013 26
Boehringer Ingelheim GmbH - Phase II, 2013 27
Boehringer Ingelheim GmbH - Phase I, 2013 28
Boehringer Ingelheim GmbH - Preclinical, 2013 30
Boehringer Ingelheim GmbH - Discovery, 2013 31
Boehringer Ingelheim GmbH - Pipeline by Therapeutic Class, 2013 114
Boehringer Ingelheim GmbH - Pipeline by Target, 2013 117
Boehringer Ingelheim GmbH - Pipeline by Route of Administration, 2013 120
Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2013 121
Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action, 2013 123
Boehringer Ingelheim GmbH - Recent Pipeline Updates, 2013 128
Boehringer Ingelheim GmbH - Dormant Developmental Projects,2013 161
Boehringer Ingelheim GmbH - Discontinued Pipeline Products, 2013 164
Boehringer Ingelheim GmbH, Subsidiaries 167 
List of Figures

Boehringer Ingelheim GmbH - Pipeline by Top 10 Indication, 2013 12
Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2013 17
Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2013 18
Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2013 20
Boehringer Ingelheim GmbH - Pipeline by Top 10 Therapeutic Class, 2013 113
Boehringer Ingelheim GmbH - Pipeline by Top 10 Target, 2013 116
Boehringer Ingelheim GmbH - Pipeline by Top 10 Route of Administration, 2013 120
Boehringer Ingelheim GmbH - Pipeline by Top 10 Molecule Type, 2013 121
Boehringer Ingelheim GmbH - Pipeline Products by Top 10 Mechanism of Action, 2013 122

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing